A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Date
2021
Author
McNeely, Samuel
Forster, Martin
Wang, Xuejing
Hynes, Scott
Lin, Aimee Bence
Byers, Lauren Averett
Navarro, Alejandro
Schaefer, Eric
Johnson, Melissa
Ozguroglu, Mustafa
Han, Ji-Youn
Bondarenko, Igor
ÇİÇİN, İRFAN
Dragnev, Konstantin H.
Abel, Adam
Metadata
Show full item record
Abstract
Patients with extensive-stage small-cell lung cancer (ED-SCLC) need improved outcomes in the relapsed/refractory setting. This phase II study evaluated the safety and efficacy of prexasertib, a checkpoint kinase 1 inhibitor, in platinum-sensitive and platinum-refractory ED-SCLC. Prexasertib demonstrated response rates of 5.2% in platinum-sensitive and 0% in platinum-refractory ED-SCLC. Prexasertib did not show prespecified efficacy as monotherapy in ED-SCLC.
URI
http://hdl.handle.net/20.500.12627/179568
https://doi.org/10.1016/j.cllc.2021.04.005
Collections